Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT06608342RecruitingPhase 2
Stem cell transplant plus CAR-T for high-risk leukemia
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06607419RecruitingPhase 2/Phase 3
Blinatumomab for leftover leukemia in children with B-ALL
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Hefei, AnhuiAges 1 month–18 years - NCT06598722RecruitingPhase 2
BCL-2 inhibitor plus HyperCVAD for T-cell lymphoma
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
ShanghaiAges 18–60 - NCT07746180RecruitingPhase 2
Obinutuzumab and low-dose steroids for new kidney disease
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
BeijingAges 18 years+ - NCT07745530Recruiting
How platelets affect HIV reservoirs in the blood
This study looks at how platelets (small blood cells that help with clotting) might influence the hidden HIV that remains in your body even when your viral load is undetectable. The goal is to understand why some people's immune systems don't fully recover despite effective HIV treatment.
TourcoingAges 18 years+ - NCT07742306Recruiting
Glucose monitor study for teens with type 1 diabetes
This study tests using a continuous glucose monitor (CGM) in teenagers with type 1 diabetes in the Dominican Republic. The device tracks blood sugar levels around the clock to help manage their diabetes better. Participants will get support and education over about 15 months.
Santiago de los CaballerosAges 10–19 - NCT07744373Recruiting
Breast milk study for infant food tolerance
This study looks at cells and molecules in breast milk that may affect how babies develop tolerance to foods. If you are a mother exclusively breastfeeding and your baby is under 9 months old, you may be able to join.
IstanbulAges birth–9 months - NCT07745426RecruitingPhase 2
Comparing add-on treatments for rheumatoid arthritis
This trial compares two additional medicines (diosmin or rebamipide) taken with standard arthritis treatment to see if they help reduce joint pain and swelling better than standard treatment alone.
TantaAges 18–70 - NCT07746921Recruiting
Smart inhaler and remote asthma care for teens with intellectual disabilities
This study tests a smart inhaler and a phone app to help teenagers with mild-to-moderate intellectual or developmental disabilities manage their asthma at home. It aims to see if this technology improves asthma control and makes it easier for families to track medication use.
Los Angeles, CaliforniaAges 10–17 - NCT07746427Recruiting
Mindfulness program on a phone or tablet for teens with eczema
This study tests a digital mindfulness program to help teens manage their eczema. It looks at whether this approach can reduce symptoms and improve quality of life.
New York, New YorkAges 13–17 - NCT07743242Recruiting
Study of hemolytic anemia in antiphospholipid syndrome
This study looks at how autoimmune hemolytic anemia (when the body attacks its own red blood cells) relates to antiphospholipid syndrome (a condition that increases blood clot risk). It aims to better understand this connection, which may help improve care for people with both conditions.
Al Khārjah, Kharga OasisAges 18 years+ - NCT03131726RecruitingPhase 3
Simvastatin for Graves eye disease in mild-to-moderate cases
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
MalmöAges 18–70 - NCT06581640RecruitingPhase 2
BCMA-targeting CAR-T cells for relapsed/refractory myeloma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Xiamen, FujianAges 18–80 - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT04638790RecruitingPhase 3
First treatment chemotherapy study for newly diagnosed Hodgkin lymphoma
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Ages 18–50 - NCT06617741Recruiting
Global Registry for Myasthenia Gravis Patients
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Westborough, MassachusettsAges 18 years+ - NCT04238143Recruiting
Knee and other joint arthritis tissue therapy
This trial tests a regenerative therapy made from a patient’s own fat tissue (a “cellular” treatment) to reduce pain and improve function in arthritis-related problems. It may help people with inflammatory or degenerative arthritis changes, if they meet safety and tissue-donation requirements.
Valencia, CaliforniaAges 18–90 - NCT06418477RecruitingPhase 2
A study of 4 drugs for a rare kidney disease
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06499233RecruitingPhase 4
Study on preventing pneumocystis pneumonia in autoimmune disease
This trial tests whether a preventive treatment can stop pneumocystis pneumonia (a lung infection) in people with autoimmune inflammatory rheumatic diseases who are taking steroids or other immune-suppressing medicines. It aims to find the safest and most effective way to protect you from this serious infection.
Wuhan, HubeiAges 18 years+ - NCT07735221Recruiting
Peanuts for stress and heart health
This trial tests whether eating peanuts every day can reduce stress, improve immune function, and lower inflammation in people who feel stressed. If you are stressed and generally healthy, you may qualify.
Davis, CaliforniaAges 18–65 - NCT07738978Recruiting
Movement and health study for paralysis
This study is looking at ways to improve movement and health for people with paralysis from conditions like spinal cord injury, stroke, traumatic brain injury, or multiple sclerosis. It involves exercises and may include electrical stimulation to help your leg and trunk muscles work better.
Cleveland, OhioAges 18 years+ - NCT07735650Enrolling by invitation
Safe withdrawal of immune meds after liver transplant
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
TaoyuanAges 20 years+ - NCT07732660Recruiting
Building skills and reducing stigma for young people with HIV in Zambia
This trial helps young people aged 18 to 24 living with HIV in three districts of Zambia. It aims to reduce stigma and build job skills to improve their lives.
Lusaka, Lusaka ProvinceAges 18–24
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.